Comparison of strategies targeting Raf-1 mRNA in ovarian cancer

International Journal of Cancer

Volumn 118, Issue 6, 2006, Pages 1565-1571

  Mullen, Peter ^a   McPhillips, Fiona ^a   Monia, Brett P ^b   Smyth, John F ^a   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; Ovarian; Raf 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BROXURIDINE; CARBOPLATIN; CGP 69846A; ISIS 13650; LIPOCORTIN 5; MESSENGER RNA; PACLITAXEL; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-RAF; RNA INTERFERENCE; THIONUCLEOTIDES;

EID: 33644540478     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21520     Document Type: Article

References (21)

1. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-6.
2. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6.
3. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
4. Storm SM, Cleveland JL, Rapp UR. Expression of raf family of proto-oncogenes in normal mouse tissues. Oncogene 1990;5:345-51.
5. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289-305.
6. McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP. Association of c-Raf expression with survival and its targeting with antisense ODNs in ovarian cancer. Br J Cancer 2001;85:1753-8.
7. Mullen P, McPhillips F, MacLeod K, Monia B, Smyth JF, Langdon SP. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clin Cancer Res 2004;10:2100-8.
8. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2:668-75.
9. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 1996;93:15481-4.
10. Lau QC, Achenbach TV, Borchers O, Muller R, Slater EP. In vivo pro-apoptotic and antitumor efficacy of a c-Raf antisense phosphorothioate ODN: relationship to tumor size. Antisense Nucleic Acid Drug Dev 2002;12:11-20.
11. Stevenson YP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwon TJ, Holmlund J, Dorr FA, O'Dwyer PJ. Phase I clinical/ pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense ODN ISIS 5132 (CGP 69846A). J Clin Oncol 1999;17:2227-36.
12. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS. c-raf-1 depletion and tumour responses in patients treated with the c-raf-1 antisense ODN ISIS 5132 (CGP 69846A). Clin Cancer Res 1999;5:3977-82.
13. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J. A phase I trial of c-Raf kinase antisense ODN ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000;6:1626-31.
14. Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer; a NCI of Canada Clinical Trials group study. Clin Cancer Res 2002;8:2188-92.
15. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense ODNs ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2002;8:2530-5.
16. Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, Nicklin P. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 1996;24:630-7.
17. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
18. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988;48:6166-72.
19. Levack PA, Mullen P, Anderson TJ, Miller WR, Forrest AP. DNA analysis of breast tumour fine needle aspirates using flow cytometry. Br J Cancer 1987;56:643-6.
20. Biroccio A, Leonetti C, Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 2003;22:6579-88.
21. Kasid U, Dritschillo A. Raf antisense oligonucleotide as a tumor radiosensitizer. Oncogene 2003;22:5876-84.